, after jumping 2.3 percent to $62.57, the highest price since at least 1980, according
data compiled by Bloomberg.
Abbott, Bristol-Myers Squibb Co. (BMY), Gilead Sciences Inc. (GILD), Vertex Pharmaceuticals Inc. and Merck & Co. are seeking a cure that doesn’t need interferon, an injection tied to flu-like side effects. The Abbott data is good enough to get U.S. approval if supported in larger trials, said Scott Brun, vice president of infectious disease development.